Breaking Finance News

Janney Montgomery Scott issued a report on Intellia Therapeutics Inc (NASDAQ:NTLA), stepping up its target to $29.00 earlier today

Reporting a potential upside of 0.71%, Janney Montgomery Scott upped the price target of Intellia Therapeutics Inc (NASDAQ:NTLA) to $29.00

Having a price of $16.91, Intellia Therapeutics Inc (NASDAQ:NTLA) traded 0.65% higher on the day. With the last close down -23.52% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. NTLA has recorded a 50-day moving average of $20.00 and a 200-day moving average of $22.25. 100,424 shares of Intellia Therapeutics Inc exchanged hands, down from an avg. volume of 227,869

Performance Chart

Intellia Therapeutics Inc (NASDAQ:NTLA)

Intellia Therapeutics Inc has a 52 week low of $16.60 and a 52 week high of $30.40 The company’s market cap is currently $0.

More About Intellia Therapeutics Inc (NASDAQ:NTLA)

Intellia Therapeutics, Inc. is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company's CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing. Its portfolio includes CRISPR/Cas9 platform technology, delivery technologies and nucleic acid modifications for human therapeutic use. The Company's CRISPR/Cas9 platform components include the guide ribonucleic acid (RNA) and the Cas9 nuclease (the genetic scissors). It has access to various delivery modalities specific to various in vivo and ex vivo approaches. The Company focuses on engineering ex vivo CRISPR/Cas9 cell therapies for chimeric antigen receptor T cell (CAR-T) and hematopoietic stem cell (HSC) applications. It also focuses on the use of in vivo Lipid Nanoparticle (LNP) delivery technology.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *